Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Alphamab Oncology banner

Alphamab Oncology
HKEX:9966

Watchlist Manager
Alphamab Oncology Logo
Alphamab Oncology
HKEX:9966
Watchlist
Price: 8.89 HKD -4.82%
Market Cap: HK$8.6B
Write Note Create Alert Ask AI

Bankruptcy Probability

Alphamab Oncology's probability of bankruptcy is 1%, making a collapse highly unlikely. The solvency score is 99/100 — a strong indicator of financial stability.

We take all the information about a company's solvency (such as how easily a company can pay interest on its outstanding debt, how much cash it has, the amount of debt, and more) and use it to estimate the probability of bankruptcy.

Very Low
Probability of Bankruptcy

Financial Position

Cash & ST Investments
+
3Y
-4%
5Y
-34%
10Y
-
Long-Term Investments
+
3Y
-
5Y
-
10Y
-
Debt
+
3Y
-39%
5Y
-37%
10Y
-

Solvency Ratios

Solvency Ratios Comparison
Alphamab Oncology Competitors

Country Company Market Cap D/E D/A Interest
Coverage 		Altman
Z-Score 		Quick
Ratio 		Current
Ratio 		Cash
Ratio
CN
Alphamab Oncology
HKEX:9966
8.5B HKD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Abbvie Inc
NYSE:ABBV
403.4B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Astria Therapeutics Inc
NASDAQ:ATXS
326.4B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Amgen Inc
NASDAQ:AMGN
205.6B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
182.9B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.9B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.4B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
NL
argenx SE
XBRU:ARGX
43.5B EUR
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
AU
CSL Ltd
ASX:CSL
70.2B AUD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
No Stocks Found

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Is Alphamab Oncology at risk of bankruptcy?

Alphamab Oncology's probability of bankruptcy is 1%, making a collapse highly unlikely.

The probability of bankruptcy is estimated using credit risk models that assess its financial health, debt levels, interest coverage, and other solvency indicators.

How much debt does Alphamab Oncology have?

As of the latest report, Alphamab Oncology has total debt of 114.1m CNY. This includes both short-term (0 CNY) and long-term (114.1m CNY) debt.

You can find a full breakdown on its Balance Sheet.

Back to Top
ALPHA SPREAD
Follow us
Join more than 320,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.